fenofibric acid has been researched along with Macular Edema in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ansquer, JC; Aubonnet, P; MacuFEN Study Investigators, FT; Massin, P; Peto, T | 1 |
| Nie, J; Wang, F; Wang, H; Zhang, C | 1 |
| Garcia-Ramírez, M; Hernández, C; Palomer, X; Simó, R; Vázquez-Carrera, M | 1 |
| Corraliza, L; Garcia-Ramírez, M; Hernández, C; Simó, R; Villarroel, M | 1 |
1 review(s) available for fenofibric acid and Macular Edema
| Article | Year |
|---|---|
Protective factors in diabetic retinopathy: focus on blood-retinal barrier.
Topics: Animals; Blood-Retinal Barrier; Diabetic Retinopathy; Erythropoietin; Fenofibrate; Humans; Insulin-Like Growth Factor Binding Protein 3; Macular Edema; Protective Factors; Pyrazines; Sitagliptin Phosphate; Triazoles; Vascular Endothelial Growth Factor A | 2014 |
1 trial(s) available for fenofibric acid and Macular Edema
| Article | Year |
|---|---|
Effects of fenofibric acid on diabetic macular edema: the MacuFen study.
Topics: Anticholesteremic Agents; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Double-Blind Method; Female; Fenofibrate; Humans; Macula Lutea; Macular Edema; Male; Middle Aged; Prospective Studies; Tomography, Optical Coherence; Triglycerides; Visual Acuity | 2014 |
2 other study(ies) available for fenofibric acid and Macular Edema
| Article | Year |
|---|---|
Fenofibrate prevents the disruption of the outer blood retinal barrier through downregulation of NF-κB activity.
Topics: Blood-Retinal Barrier; Capillary Permeability; Cells, Cultured; Cytokines; Diabetic Retinopathy; Down-Regulation; Fenofibrate; Humans; Interleukin-1beta; Interleukin-6; Macular Edema; Retinal Pigment Epithelium; Signal Transduction; Transcription Factor RelA | 2016 |
Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation.
Topics: Aged; AMP-Activated Protein Kinases; Biological Transport; Blood-Retinal Barrier; Cell Line; Cell Membrane Permeability; Dextrans; Diabetic Retinopathy; Dose-Response Relationship, Drug; Fenofibrate; Fluorescein-5-isothiocyanate; Glucose; Humans; Hypolipidemic Agents; Interleukin-1beta; Macular Edema; Retinal Pigment Epithelium; Tight Junctions | 2011 |